Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07400198 · ClinicalTrials.gov registry record
Gait and Bone Health in SMA
A clinical trial of Spinal Muscular Atrophy Type 3 and Ambulatory Spinal Muscular Atrophy, sponsored by Jacqueline Montes.
- Recruiting
- Registry status
- 22
- Enrollment target
- 1
- Study location
NCT07400198: Recruiting study of Spinal Muscular Atrophy Type 3 and Ambulatory Spinal Muscular Atrophy, sponsored by Jacqueline Montes.
NCT07400198 is a study of Spinal Muscular Atrophy Type 3 and Ambulatory Spinal Muscular Atrophy that is actively recruiting participants, run by Jacqueline Montes. The registered enrollment target is 22 participants, below the 93-participant average among 9 other Spinal Muscular Atrophy Type 3 trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07400198, a study of Spinal Muscular Atrophy Type 3 and Ambulatory Spinal Muscular Atrophy, is actively recruiting participants, sponsored by Jacqueline Montes.
- RECRUITING
- Registry status
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to understand how spatiotemporal and kinetic gait parameters are associated with bone health in pwSMA who are receiving DMT. We hypothesize that gait parameters are associated with BMD and can determine fracture risk in pwSMA. This is an observational study that involves one in-clinic visit (approximately 3 hours) with remote follow-up visits (approximately 15 minutes) every 3 months for 1 year to collect fracture and medical history. Each of the assessments included in this study are non-interventional and are not intended as a treatment nor are they at the level of standard of care.
Primary Outcome
Bone mineral density (BMD), a measure of the mineral content in bones is assessed using dual x-ray absorptiometry (DXA). DXA can be used to identify individuals with low bone mass (LBM). DXA uses low-power x-ray and is a safe and reliable measure validated to diagnose osteoporosis. DXA provides a t-score and z-score so that based on age, low bone mass can be appropriately determined. DXA also provides a subtotal BMD score as well as scores specific to certain body regions, both of which will be
Conditions Studied
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2026-03-05 |
| Est. Completion | 2027-06-30 |
What NCT07400198 shows while recruiting
NCT07400198 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 93-participant average among 9 other Spinal Muscular Atrophy Type 3 trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Spinal Muscular Atrophy Type 3 appearing as the primary indexed condition, and to 0 interventions.
NCT07400198 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07400198 about?
NCT07400198 is a clinical study titled "Gait and Bone Health in SMA". The objective of this study is to understand how spatiotemporal and kinetic gait parameters are associated with bone health in pwSMA who are receiving DMT. We hypothesize that gait parameters are associated with BMD and can determine fracture risk in pwSMA. This is an observational study that involv...
What is the current status of trial NCT07400198?
This trial is currently recruiting. The enrollment target is 22 participants. The study started on 2026-03-05. Estimated completion is 2027-06-30.
What conditions does trial NCT07400198 study?
This clinical trial studies the following conditions: Spinal Muscular Atrophy Type 3, Ambulatory Spinal Muscular Atrophy.
Who is sponsoring clinical trial NCT07400198?
This trial is sponsored by Jacqueline Montes, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07400198 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Muscular Atrophy Type 3
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07400198's enrollment target sits among peer trials
22 8th of 9 higher than 2 of 9 other Spinal Muscular Atrophy Type 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Spinal Muscular Atrophy Type 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
RECRUITING
-
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
RECRUITING · Phase 2
-
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
ACTIVE NOT RECRUITING · NA
-
Spinraza in Adult Spinal Muscular Atrophy
ACTIVE NOT RECRUITING
-
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
ACTIVE NOT RECRUITING · Phase 3
-
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI